Introduction {#sec1}
============

In light of evidence of H~2~S production in rat, bovine, and human brain tissues,^[@ref1],[@ref2]^ interest has intensified in its role as the third gaseous "hormone."^[@ref3],[@ref4]^ In particular, H~2~S appears to be an important actor in modulating cell function in the vasculature and in the cerebrum. Three enzymes^[@ref5]−[@ref7]^ have been reported to produce H~2~S endogenously, namely, (i) cystathionine β-synthase (CBS; EC 4.2.1.22), (ii) cystathionine γ-lyase (CSE; EC 4.4.1.1), and (iii) 3-mercaptopyruvate sulfurtransferase (3-MST; EC 2.8.1.2). CBS and CSE eliminate H~2~S from [l]{.smallcaps}-cysteine, whereas 3-MST reductively releases H~2~S from 3-mercaptopyruvate, itself a product of [l]{.smallcaps}-cysteine transamination via cysteine aminotransferase (CAT). \[*In vitro*, CSE actually eliminates H~2~S 3-fold more efficiently from [l]{.smallcaps}-homocysteine than from [l]{.smallcaps}-cysteine; however, physiological concentrations of the latter (100 μM) are estimated to be 10-fold higher than those of the former (10 μM), making [l]{.smallcaps}-cysteine the principal biological H~2~S donor for CSE as well.^[@ref8]^\] Thioredoxin appears to be the best candidate for the *in vivo* reductant in the 3-MST reaction. Once released, H~2~S may serve as (i) a signaling molecule itself or is transformed into (ii) sulfhydrated protein (e.g., through reaction with a protein disulfide), or into (iii) polysulfides or into (iv) HSNO upon reaction with NO, another prominent gaseous neuromodulator (a one electron oxidation).^[@ref9]^ So while the mechanism for H~2~S-signaling is clearly complex, potentially divergent, and incompletely understood, important functions have been associated with H~2~S-signal transduction in both the cerebrum and the vasculature.

Interestingly, all three biogenetic pathways into H~2~S emanate from [l]{.smallcaps}-cysteine and involve a pyridoxal phosphate (PLP)-dependent enzyme. The expression of these enzymes seems to be tissue-specific. CSE has been shown to be primarily involved with H~2~S production in the cardiovascular system.^[@ref10]^ Conversely, studies have indicated that CBS serves as the primary machinery for H~2~S production in the brain, and its expression is highly concentrated in the astrocytes.^[@ref11],[@ref12]^ Understanding of H~2~S in terms of its biogenesis, *in vivo* concentration, bioenergetics, and activity is still in its infancy, with the ability to measure H~2~S levels *in vivo* being one of the principal challenges, particularly given that it may be "stored" in various releasable forms. A number of recent reviews^[@ref9],[@ref13]−[@ref17]^ on H~2~S provide an overview of the complexity of signaling activities ascribed to H~2~S as an effector molecule. To further our understanding of the protective and deleterious effects associated with H~2~S going forward, a combination of genetics and chemical biology will likely be needed. There also is great interest in developing new and more effective H~2~S-sensing platforms.^[@ref18]−[@ref25]^ At this stage, tools that allow for the modulation of CBS activity in the astrocytes \[and correspondingly of CAT/3-MST activity and/or CSE activity in the vasculature\] would be valuable tools to chemical biologists seeking to understand H~2~S activity as a function of tissue location; concentration; cellular conditions; and source ([l]{.smallcaps}-cysteine, [l]{.smallcaps}-homocysteine, stored sulfane repository or elemental S).

H~2~S Biogenesis {#sec1.1}
----------------

Illustrated in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a are the two key biological reactions mediated by CBS (coordinates for PDB 1M54 shown).^[@ref26]^ The reaction on the lower left represents the role of CBS in the transsulfuration pathway through which sulfur in essential dietary [l]{.smallcaps}-methionine is transformed into essential cellular redox equivalents in the form of glutathione. Specifically, CBS condenses [l]{.smallcaps}-serine with [l]{.smallcaps}-homocysteine in a β-replacement reaction, producing a molecule of ([l]{.smallcaps},[l]{.smallcaps})-cystathionine and water. This effectively moves the sulfur atom from its [l]{.smallcaps}-methionine source to its [l]{.smallcaps}-cysteine destination. (The methyl group from [l]{.smallcaps}-methionine is transferred elsewhere through the sequential action of three enzymes: SAM synthetase, SAM-dependent methyl-transferases, and SAH hydrolase. The resultant [l]{.smallcaps}-homocysteine transfers its sulfur atom to the β-carbon of [l]{.smallcaps}-serine through the consecutive action of two PLP-enzymes, namely, CBS, forming ([l]{.smallcaps},[l]{.smallcaps})-cystathionine and CSE, breaking ([l]{.smallcaps},[l]{.smallcaps})-cystathionine down to [l]{.smallcaps}-cysteine, α-ketobutyrate, and ammonia.) The second major CBS activity, illustrated in the upper right section of [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a, represents the primary H~2~S-source in the mammalian brain. A suite of CBS-mediated transformations exists, through which [l]{.smallcaps}-cysteine is paired with a cosubstrate to produce a molecule of H~2~S, either by a β-replacement or a β-elimination reaction. Elegant and comprehensive kinetic studies by Banerjee and co-workers^[@ref27]^ have demonstrated (i) the promiscuity of this enzyme in accepting a variety of nucleophiles in the H~2~S-generating β-replacement manifold; (ii) that the by product(s) distribution associated with H~2~S production is dependent upon the available nucleophiles, their physiological concentrations, and their relevant kinetic parameters (*K*~m~, *k*~cat~, and *k*~cat~/*K*~m~); (iii) that under both maximal velocity and physiological substrate concentrations, β-replacement of cysteine by homocysteine is primarily responsible for H~2~S production by CBS; and (iv) at high substrate concentrations, CBS accounts for ∼95% of the total H~2~S output in the brain.

![(a) β-Replacement reaction mediated by PLP-dependent CBS between [l]{.smallcaps}-serine and [l]{.smallcaps}-homocysteine to produce [l]{.smallcaps},[l]{.smallcaps}-cystathionine (lower left reaction). CBS represents the primary contributor of H~2~S in the mammalian brain via either β-replacement or β-elimination reactions emanating from [l]{.smallcaps}-cysteine (upper right reaction). (b) A few possible effects of elevated H~2~S levels on neurological outcomes pursuant to stroke: (i) cAMP-dependent PKA activation leading to possible NMDA receptor phosphorylation and increased activity; (ii) H~2~S enhancement of Ca^2+^ flux into the post-synaptic neuron by H~2~S-release from NMDA receptor-bound polysulfides (stored sulfane sulfur); (iii) following an inflammatory trigger, elevated H~2~S levels may augment signaling pathways involved in activating inflammatory cells (microglial cells) causing a discharge of mediators such as chemokines and cytokines that could further damage the neuron, exacerbating neuronal cell death. (c) Schematic illustrating the design principles of a library of CBS-targeted affinity-based inhibitors designed to incorporate recognition features of the CBS product, [l]{.smallcaps},[l]{.smallcaps}-cystathionine. These inhibitor candidates were envisioned to engage the active-site PLP cofactor, forming tight binding hydrazone, oxime, or nitrone adducts.](oc-2016-00019a_0003){#fig1}

H~2~S Forms and Concentrations {#sec1.2}
------------------------------

Estimates by a variety of techniques place endogenous cerebral H~2~S concentration in the range of 1--160 μM,^[@ref1],[@ref2],[@ref9]^ or even sub-micromolar with a new monobromobimane-based assay.^[@ref28]^ It might seem that such low H~2~S levels would be insufficient to induce the range of physiological responses reported. However, more recently, Shibuya et al. and others^[@ref7],[@ref29]^ have found that H~2~S may be stored in the form of polysulfides or protein persulfides formed through the process of sulfhydration. This protein-bound sulfur appears to function as an intracellular storage form of H~2~S. In these studies, H~2~S is released in the presence of a redox active thiol such as thioredoxin, or perhaps glutathione. Thus, actual H~2~S concentrations may vary significantly as a function of cellular redox potential. Increased calcium influx to astrocytes has also been reported to actuate release of the signaling molecule [d]{.smallcaps}-serine, a coagonist of the *N*-methyl [d]{.smallcaps}-aspartate receptor (NMDAR), thereby potentiating the H~2~S-signal at this receptor while signifying possible cross-talk between two PLP-dependent enzymes in the brain, CBS and serine racemase, with attendant consequences for neuronal cell damage pursuant to stroke.

Protective vs Deleterious Effects of H~2~S as a Function of Concentration {#sec1.3}
-------------------------------------------------------------------------

The role of H~2~S in the inflammatory response, another source of neuronal damage ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b, schematic iii), has been the subject of considerable debate with both pro- and anti-inflammatory roles for H~2~S having been described. Research from Whiteman has shown that the effect of H~2~S on inflammation is a concentration-dependent response and is dependent upon the rate of H~2~S generation.^[@ref30]^ The pioneering work of Abe and Kimura showed that high levels of H~2~S (130 μM) selectively increase NMDAR-mediated currents in hippocampal slices.^[@ref31]^ Later, this same group reported ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b, schematic i) that H~2~S effects on the NMDAR are associated with an increase in the secondary messenger, cAMP, suggesting the activation of adenylate cyclase.^[@ref32]^ Elevated H~2~S levels have been implicated in a wide range of abnormalities and diseases. Relevant to the collaborative work described herein, Wong et al. observed that high plasma cysteine levels correlated with poor clinical outcome of patients suffering from acute stroke.^[@ref33]^ In the same study, in an experimental model for stroke on rats, middle cerebral arterial occlusion (MCAO) measurements of brain infarction volumes were elevated upon exogenous introduction (IP or ICV) of cysteine prior to the occlusion, in a dose-dependent manner. A similar effect was also observed when an H~2~S donor, NaSH, was administered. The hypothesis that the cysteine effect was due to its conversion to H~2~S by CBS was further supported when pretreatment with aminooxyacetic acid (AOAA), a generic PLP-enzyme inhibitor, served to counteract these effects. Confirmatory evidence for high H~2~S concentrations leading to enhanced cell death under ischemia was obtained in cells overexpressing CBS after knocking in of the CBS gene.^[@ref34]^ Moreover, brain 3-MST activity has been seen to be down-regulated following acute stroke,^[@ref35]^ lending additional support to the notion that CBS is the key enzyme modulating levels of cysteine-derived H~2~S in the cerebral cortex and that H~2~S mediates ischemic damage pursuant to stroke.

Results and Discussion {#sec2}
======================

Design and "Zipped Synthesis" of CBS Inhibitor Array by Cross-Metathesis {#sec2.1}
------------------------------------------------------------------------

As mentioned above, all three biogenetic routes to H~2~S involve PLP-enzymes, but it is CBS that serves as the principal source of H~2~S biogenesis in the brain. Given the evidence implicating elevated cerebral H~2~S levels in ischemic neuronal damage, CBS inhibitor development has emerged as an area of considerable interest. Owing to the dearth of such inhibitors, previous studies have relied upon generic PLP-enzyme inhibitors such as AOAA to modulate CBS activity. To address this, a central goal of this study was to develop CBS-targeted inhibitors and explore their utility as tools for chemical biology. Indeed, the Berkowitz laboratory explores problems at the interface of synthetic organic chemistry and mechanistic enzymology,^[@ref36],[@ref37]^ with a longstanding interest in the inhibition of PLP-dependent enzymes.^[@ref38]−[@ref44]^ And the Wong laboratory has made a dedicated effort to develop *in vitro* and animal models for stroke, with a particular interest in H~2~S-signaling.^[@ref34],[@ref45]^ These complementary approaches set the stage for the collaborative chemistry/neurobiology studies detailed herein.

An array of CBS-targeted inhibitors was envisioned, based upon structural, synthetic, and mechanistic considerations. (i) Structurally, the notion was to construct a series of compounds with shape and charge complementarity to ([l]{.smallcaps},[l]{.smallcaps})-cystathionine, the particular CBS reaction product that presents the greatest number of binding recognition elements for the enzyme and that also exhibits the tightest binding to the enzyme (*K*~m~ ≈ 83 μM vs mM *K*~m~ values for [l]{.smallcaps}-serine, [l]{.smallcaps}-cysteine, and [l]{.smallcaps}-homocysteine).^[@ref46]^ (ii) Synthetically, the pseudo-*C*~2~-symmetry present in the ([l]{.smallcaps},[l]{.smallcaps})-cystathionine structure would provide the key to a streamlined "zipped synthesis" route into the inhibitor library. (iii) Finally, mechanistically, these inhibitors were designed by careful consideration of pyridoxaldimine chemistry in PLP-enzyme active sites. Namely, the inhibitor candidates were designed to be outfitted with vicinal heteroatomic functional groups (-NHNH~2~, -ONH~2~, -NHOH) in place of the usual α-amino groups. This is because such derivatives have the potential to display especially favorable binding kinetics with respect to cofactor-adduction. This is borne out by a careful survey of the literature, as is laid out in detail in [Figure S10](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.6b00019/suppl_file/oc6b00019_si_001.pdf) of the Supporting Information. Whereas for α-hydrazino acids, imine-hydrazone interchange (i.e., transaldimination) is 1--2 orders of magnitude slower than the corresponding imine--imine interchange for native α-amino acid substrates in the forward direction (i.e., *k*~on~), the reverse reaction is some 4--6 orders of magnitude slower (i.e., *k*~off~) for the former (*t*(1/2)~off~ ≈ 0.02--1 s) vs the latter (*t*(1/2)~off~ ≈ 2.5 h). In simple terms, the price that one pays in terms of attenuated *k*~on~ kinetics is more than compensated for by greatly diminished *k*~off~ rates for the α-hydrazino-acids vs α-amino-acids resulting in an anticipated ∼10^3^-fold advantage in effective equilibrium constant for covalent cofactor adduction for such compounds.

Following this analysis, we chose to design our library as is illustrated in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}c, retrosynthetically replacing the central thioether linkage with an "isosteric" C=C linkage. (Consider here the difficulty of separating thiophene impurities from benzene. In this case, after replacing the central S with at C=C element, a single methylene is removed so as convert a pseudosymmetric inhibitor target into a perfectly symmetrical one). This introduces actual *C*~2~-symmetry into the inhibitor design, and, most importantly, enables these inhibitors to be "zipped" together by Grubbs cross-metathesis chemistry^[@ref47]^ from a single "half-inhibitor" precursor, greatly streamlining the chemistry. The broad functional group compatibility^[@ref48]^ of the metathesis chemistry makes it especially appropriate for this application in chemical biology. Highlighted in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} are the key synthetic transformations leading to the focused library of CBS inhibitor candidates targeted herein. Starting from (*S*)-glycidol, *O*-THP-protection, and vinyl cuprate-mediated epoxide ring-opening efficiently yield the important [d]{.smallcaps}-α-hydroxy-4-pentenol-derived chiral synthon **3**. Compound **3** proved to be a key common intermediate for a series of modified Mitsunobu reactions (∼70% yield for each series) in which the Cα-hydroxyl group is stereospecifically substituted with an α-effect nucleophile, with inversion of configuration, giving (i) the bis-Boc-protected hydrazine **4**, (ii) the *N*-phthalimide-protected aminooxy compound **7**, or (iii) the *N*-Boc-*O*-*o*-nitrobenzyl-protected hydroxylamine **10**. The zipped approach of streamlining the construction of such inhibitors by exploiting *C*~2~-symmetry proved to be quite effective, allowing for swift assembly of the carbon backbone via convergent alkene cross-metathesis. The Grubbs first generation catalyst serves to zip together the two halves of the targeted inhibitors quite cleanly ("spot to spot" reactions, albeit with two geometric isomers being formed; ∼80% yields). Following these convergent cross-metathesis transformations, tailoring chemistry was performed in order to separate the geometric isomers and set the desired oxidation state. These operations include (i) *O*-THP-deprotection, (ii) Jones oxidation, and finally (iii) a convenient global deprotection strategy to unveil a 3 × 3 array of CBS inhibitor candidates.

![Detailed routes for the "zipped synthesis" of the array of CBS inhibitor candidates.](oc-2016-00019a_0004){#fig2}

Enzyme Kinetics: CBS Inhibition Studies {#sec2.2}
---------------------------------------

CBS inhibition assays were performed on the heterologously expressed human enzyme, hCBSΔC143 construct. This truncated form of the enzyme lacking the C-terminal regulatory domain is known to form a highly active dimeric enzyme that has been characterized structurally.^[@ref49]^ A comprehensive assessment of inhibitor candidate fitness was conducted utilizing three distinct assays for hCBS activity: (i) a modified continuous assay, exploiting microscopic reversibility, allowed for measurement of the cystathionine-lyase activity of hCBS, followed by trapping of the [l]{.smallcaps}-homocysteine produced with 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman's reagent) and spectroscopically quantifying the *m*-carboxy-*p*-nitrothiophenolate anion (λ~max~ = 412 nm; Δε~412~ = 13 600 M^--1 ^cm^--1^) thereby released; (ii) a radioactive label-based assay reporting on the forward transsulfuration reaction catalyzed by hCBS using ^14^C-labeled [l]{.smallcaps}-serine in the presence of [l]{.smallcaps}-homocysteine to measure ^14^C-labeled ([l]{.smallcaps},[l]{.smallcaps})-cystathionine product. And, most importantly, (iii) a modified H~2~S-sensing assay to measure hCBS-catalyzed production of H~2~S from [l]{.smallcaps}-cysteine. Capture of the H~2~S produced by Pb(OAc)~2~ leads to the formation of PbS and a concomitant increase in Abs~300~ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a,b).

![Results from kinetic analysis of inhibitor candidates with the hCBS truncated dimer. (a) Lineweaver--Burk plot for hCBS inhibition with **6S**, detecting H~2~S production in the presence Pb(OAc)~2~. (b) Secondary-plot of bis-α-hydrazino acid (**6S**) inhibition of H~2~S production by hCBS yielding a *K*~i~ value of 48 ± 2 μM. (c) UV/vis spectroscopic profile of model PLP-inhibitor adducts formed nonenzymatically. Conditions: 0.26 mM hydrazino acid **6S**, 0.2 mM PLP, 50 mM KPO~4~ (pH 8.0), scans every 10 min, isosbestic point = 355 nm, *t*~1/2~ = 7 min (left spectrum); conditions: 0.33 mM aminooxy acid **9**S, 0.2 mM PLP, 50 mM KPO~4~ (pH 8.0), scans recorded every 10 min, isosbestic point = 360 nm, *t*~1/2~ = 15 min (right spectrum).](oc-2016-00019a_0005){#fig3}

Both the ([l]{.smallcaps},[l]{.smallcaps})-cystathionine lyase-activity and radioactive assay identified the fully saturated α-([l]{.smallcaps},[l]{.smallcaps})-bis-hydrazino acid **6S** to be the most potent CBS inhibitor candidate (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.6b00019/suppl_file/oc6b00019_si_001.pdf)). Furthermore, It should be noted that assays involving the hydroxylamino acid compounds **12E**, **12Z**, and **12S** (designed as "nitrone-formers") were not compatible with the continuous assay. When tested in the radioactive assay, both the aminooxy (-ONH~2~ series) and hydrazino acid (-NHNH~2~ series) inhibitor classes significantly outperformed the hydroxylamino acid class (-NHOH series). This is consistent with the spectroscopic studies involving incubation with PLP directly (see below and [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c), the results of which point to the greater predilection of PLP to engage in hydrazone (-NHNH~2~ series) and oxime (-ONH~2~ series) linkages, in comparison with nitrone linkages (-NHOH series). Given the promise associated with the hydrazone-forming strategy in particular here, further kinetic analysis was performed on the most promising inhibitor candidate, **6S**, this time monitoring its effect on CBS-mediated H~2~S formation directly. Using the aforementioned Pb-based spectrophotometric H~2~S sensing assay, **6S** was found to display a kinetic pattern consistent with clean competitive inhibition of the CBS with respect to [l]{.smallcaps}-cysteine, yielding *K*~*i*~ = 48 ± 2 μM.

As noted, to test the inhibitor design strategy, a series of model experiments was conducted by incubation of specific inhibitor candidates of each functional group class with PLP in solution. PLP-adduct formation with the saturated inhibitor candidates **6S**, **9S**, and **12S** was monitored by UV/vis spectroscopy ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c). These model experiments were deemed particularly important because hCBS contains a critical heme domain that absorbs broadly in the UV/vis from 325 to 500 nm,^[@ref49]^ thereby blocking the spectral region in which one typically observes the active site internal PLP-aldimine (λ~max~ ≈ 420 nm) and related PLP-adducts. Displayed in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c are the spectroscopic profiles of compound **6S** and **9S**, respectively, upon incubation with PLP. For each model experiment, the spectrum indicates that at *t* = 0 no complex has formed. The absorption peak at λ~max~ = 388 nm is attributed to free PLP; over time, additional peaks appear and the peak at 388 nm diminishes as covalent cofactor adduct formation proceeds. The projected hydrazone-forming compound **6S**, for example, when incubated with PLP, gives rise to absorbance peaks at 305 and 329 nm. A different spectroscopic signature for the putative oxime-former **9S** appears with absorbances at 270 and 325 nm. It should be noted that the saturated *N*-hydroxy amino acid compound **12S** was also tested in the same manner. However, the data do not provide evidence for the formation of a stable nitrone adduct with the cofactor under these conditions. The apparent PLP-hydrazone, on the other hand, is reminiscent of the carbidopa hydrazone that forms in the active site of peripheral DOPA decarboxylase (combination therapy for Parkinson's disease).^[@ref50],[@ref51]^ Indeed, in spectroscopic studies conducted for carbidopa^[@ref52]^ (100 μM) and PLP (10 μM) alone, hydrazone formation was characterized by two absorption bands at λ~max~ = 305 and 335 nm (*t*~1/2~ = 1.19 min) and a shoulder around 380 nm. Thus, the preponderance of evidence suggests that **6S** and **9S** are able to engage the PLP cofactor in stable hydrazone and oxime adduct linkages, respectively, but it remains an open question as to whether **12S** can engage the cofactor in a stable nitrone linkage, at least in aqueous solution. Given these encouraging results, compound **6S** was advanced into the chemical biology stage of the investigation, including examination of performance in both *in vitro* cell-based assay and *in vivo* assay using a rat middle cerebral artery occlusion model for stroke.

Neuronal Cell Culture: Oxygen/Glucose Deprivation (OGD) Model Studies {#sec2.3}
---------------------------------------------------------------------

Pleasingly, experiments designed to test the ability of **6S** to attenuate the H~2~S-synthesizing activity in brain whole cell lysates were consistent with the *in vitro* kinetic assays previously described (*K*~i~ ≈ 50 μM for H~2~S production). Moreover, in neuroblastoma model studies simulating ischemic conditions through oxygen and glucose deprivation (OGD) ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), SH-SY5Y overexpressing CBS (CBSOE cells) were treated with concentrations of [l]{.smallcaps}-cysteine and [l]{.smallcaps}-homocysteine that represent estimated physiological substrate concentrations (red),^[@ref53]^ on the one hand, and high concentrations (green), on the other. These experiments were conducted in the absence or presence of CBS inhibitor **6S** (100 and 500 μM). As shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, the cell viability of CBSOE cells was reduced to ∼50% when subjected to OGD for 24 h. When physiological substrate concentrations were used, there was no significant change in cell viability as compared to the no substrate control. However, when substrate concentrations were increased 10-fold to mimic stroke conditions, a significant loss in cell viability to \<10% was observed, presumably due to the high levels of H~2~S production through the action of CBS.^[@ref34]^ As expected, cell viability was largely restored by addition of inhibitor **6S**. Indeed, the SH-SY5Y CBS overexpressing cells responded in a dose-dependent manner (see [Figure S16](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.6b00019/suppl_file/oc6b00019_si_001.pdf) in the Supporting Information for details) to rescue with **6S**, with nearly full restoration to control levels being observed at 500 μM of inhibitor. These results are consistent with reports that the effects of H~2~S on neuronal damage^[@ref33],[@ref54]^ and macrophages^[@ref55]^ are dependent on the H~2~S concentration at the time of insult.

![Reversal of enhanced cell death in CBS-overexpressing (CBSOE) SH-SY5Y cells exposed to high CBS substrates by CBS inhibitor **6S**. (a) Fluorescence (right) and phase contrast (left) micrographs of lentiviral vector transduced SH-SY5Y CBSOE cells. Fluorescence indicates CBS-EGFP (reporter gene) expression. (b) Western blot results confirming that CBS was markedly expressed compared to nontransduced control (C) cells. Only the full length CBS (63 kDa) was detected but not the truncated CBS (45 kDa). (c) Inhibition by CBS inhibitor (CBSI) **6S** of H~2~S production in SH-SY5Y CBSOE cell homogenates in the presence of [l]{.smallcaps}-cysteine (1 mM) and [l]{.smallcaps}-homocysteine (0.1 mM). Data are presented as mean ± SEM, *n* = 3. ANOVA: F (2, 6) = 421.247, *p* \< 0.05; \*\*\**p* \< 0.001 against no inhibitor control by Bonferroni. (d) CBS inhibition by **6S** reversed the enhanced cell death in CBSOE cells subjected to OGD (24 h) in the presence of high substrates. Cell viability is expressed as fraction to control without OGD (not shown). ANOVA for high substrate conditions: F (3, 11) = 10.248, *p* \< 0.05; \*\**p* \< 0.01 against without **6S** by Bonferroni. Data are mean ± SEM, *n* = 3--4.](oc-2016-00019a_0006){#fig4}

Rat Stroke Model: Transient Middle Cerebral Artery Occlusion (tMCAO) {#sec2.4}
--------------------------------------------------------------------

Next, an *in vivo* tMCAO rat model study was undertaken to ascertain whether the observed inhibition of CBS *in vitro*, and inhibition of H~2~S biogenesis in SH-SY5Y CBS overexpressing cells lysate by **6S** would translate into attenuation of infarction volume in a rat stroke model. In the event, the middle cerebral artery was transiently blocked for 100 min to induce tissue infarction in the following 24 h window. Illustrated in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}, infarct volumes were determined in brain slices stained with TTC (2,3,5-triphenyl-2H-tetrazolium chloride). In this assay, tissues undergoing active respiration exhibit significant succinate dehydrogenase activity and this manifests itself in reduction of the TTC indicator, producing triphenylformazan (TPF) a red-colored dye. By contrast, those regions suffering from necrosis exhibit a markedly lower local redox potential, and fail to reduce the tetrazolium salt to the corresponding formazan dye, resulting in unstained regions indicative of infarction. The volume of unstained tissue relative to the hemispherical volume was then experimentally quantified and used as a measure of infarction volume. As can be seen in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}c, this lead compound **6S** (1.6 μmol/kg, intracerebroventricular injection) protected against infarction, with an 83% or 66% reduction in infarction volume being seen, relative to control when the inhibitor was injected 30 min prior to or 60 min after the start of tMCAO, respectively. These results clearly demonstrate a pharmacological effect of the inhibitor in an *in vivo* setting. In addition, **6S** appeared to have no effect on cerebral blood flow as observed in the first 30 min after administration but before the onset of tMCAO in the pretreatment group ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b). The fact that this inhibitor remained effective when given as a post-stroke treatment following the onset of occlusion is encouraging as this is the norm in the treatment of acute stroke.

![Neuroprotection by CBS inhibitor **6S** against ischemic injury induced by transient middle cerebral artery occlusion (tMCAO). (a) Inhibition of H~2~S synthesizing activity in brain homogenate at varying concentrations of CBSI 6S. Data are presented as mean ± SEM, *n* = 3--7; \*\**p* \< 0.01, \*\*\**p* \< 0.001 against no inhibitor control (C) by Bonferroni. (b) The right MCA was occluded by the insertion of a suture through the carotid artery for 100 min. The blood flow in the affected area was monitored by a Laser-Doppler device showing a reduction of about 70--75% and returned to pre-MCAO levels upon reperfusion, *n* = 7--10. (c) Infarct volumes at 24 h after tMCAO. Top panel shows representative TTC-stained forebrain sections of a vehicle-treated, a CBSI **6S**-pretreated and a CBSI **6S**-post-treated rat. CBSI **6S** or vehicle was administered by intracerebroventricular (icv) injection 30 min before tMCAO (CBSI pre-30 min) or 1 h after middle cerebral artery occlusion (CBSI post 1 h). (d) Bottom panel shows the calculated infarct volumes of the three groups, *n* = 5--10, ANOVA: F (2, 19) = 7.89, \**p* \< 0.05, \*\**p* \< 0.01 against vehicle control group by Bonferroni.](oc-2016-00019a_0007){#fig5}

Modulating the Microglial Response in the Presence of the CBS Inhibitor {#sec2.5}
-----------------------------------------------------------------------

In light of these encouraging results, experiments were also conducted to examine whether the dramatic reduction in infarct volume observed upon ICV treatment with **6S** might correlate with a reduction in microglial activation. Microglia account for 10--15% of all brain cells. In the normal brain, microglia exist as ramified star-like cells known as resting microglia. In disease or injury, microglia are first transformed into activated microglia with thicker processes and larger cell bodies, and then into large amoeboid shape phagocytic microglia. They function as scavengers through phagocytosis of dead/apoptotic cells, cellular debris, and foreign materials such as viruses and bacteria. They can also release cytotoxic free radicals and activate pro-inflammatory cytokines and chemokines. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}a shows OX-42 immunopositive microglia in the cortex and striatum. Resident microglia mostly in the resting state can be seen in the sham-operated group. The tMCAO group shows microglial activation as evidenced by the increase in number and change in morphology. However, treatment with CBS inhibitor **6S** markedly attenuates the microglial activation. Furthermore, staining for ED-1, a marker for macrophages including phagocytic microglia, shows many such cells in the tMCAO group. This marker, too, was correspondingly reduced in the CBS inhibitor-treated group. In contrast, macrophages are not detected in the sham-operated group ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}d). These observations are supported by the Western blot data ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}b,c and e, f). Overall, treatment with **6S** leads to a significant decrease in microglial activation as a result of reduced tissue damage induced by tMCAO. These results provide support for the idea that targeted blockade of H~2~S-production in ischemic tissues may dampen the inflammatory response, in addition to attenuating infarction.

![Reduction of microglial number and activation of the MCAO-affected cortex (Co) and striatum (St) by CBS inhibitor **6S**. (a) OX-42-immunopositive microglial cells observed in the Sham-operated (S) group are resting microglia based on their ramified star-like morphology. Marked increase in the number of microglia was observed in the tMCAO (T) group. Many of these cells are activated as they appeared to be large with thick processes. In the CBSI **6S**-treated tMCAO (T + I) group, the number of activated microglia was reduced although still increased when compared to the Sham group. (b) Representative Western blot results. (c) Quantified Western blot results, *n* = 3--4. ANOVA: F (2, 8) = 19.399 for cortical OX-42, F (2, 8) = 25.288 for striatal OX-42, \*\**p* \< 0.01 against respective tMCAO (T) group by Bonferroni. Western blot results support the observations in A. (d--f) are similar to (a--c) except that they are for ED-1 which is a marker of macrophages including phagocytic microglia, which are comparatively absent in the sham group. (f) ANOVA: F (2, 8) = 15.408 for cortical ED-1 and F (2, 7) = 59.718 for striatal ED-1, \*\**p* \< 0.01, \*\*\**p* \< 0.001 against respective tMCAO (T) group by Bonferroni.](oc-2016-00019a_0008){#fig6}

Conclusions {#sec3}
===========

The studies described herein articulate design elements for the inhibition of hCBS that are likely generalizable to other enzyme targets, particularly those dependent upon PLP. These design principles include (i) choosing that enzymatic product, ([l]{.smallcaps},[l]{.smallcaps})-cystathionine here, that presents the largest binding surface as a platform for inhibitor design, even if that product is not produced in the reaction being targeted for tissue-localized inhibition (H~2~S production here). Next, (ii) the pseudo-*C*~2~-symmetry in the cognate substrate may be exploited to greatly simplify inhibitor candidate construction, by allowing for the stereocontrolled synthesis of one-half of the inhibitor structure, in this case, followed by a melding of the two halves by a quite efficient Ru-mediated alkene cross-metathesis transformation mediated by the Grubbs first generation catalyst. Finally, (iii) these studies support the use of an X-Y affinity reagent functionality in place of the α-amino group to develop PLP enzyme inhibitor candidates, but, at the same time, point to the advantage of surveying a range of such X-Y functionalities as significant structure/activity relationship (SAR) may be seen.

Indeed, key results here include the observation that CBS inhibitors mimicking the ([l]{.smallcaps},[l]{.smallcaps})-cystathionine structure but bearing α-hydrazino functionality in place of the α-amino groups are most effective in blocking hCBS activity, presumably via active site PLP-hydrazone formation, consistent with model studies. The most effective inhibitor, **6S**, displays a *K*~i~ lower than the best substrate *K*~m~ yet reported (for ([l]{.smallcaps},[l]{.smallcaps})-cystathionine itself) and, to our knowledge, the lowest *K*~i~ reported to date for a competitive inhibitor of the enzyme. Compound **6S** also exhibits functional irreversible inhibition (exhaustive dialysis studies show essentially no recovery of CBS activity against two different buffer systems; see [Figure S13](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.6b00019/suppl_file/oc6b00019_si_001.pdf) and the surrounding experimental details in the Supporting Information) and consistently curtails CBS activity across three different assay platforms -- (i) cystathionine lyase and (ii) formation activities (bidirectional transsulfuration) and (iii) H~2~S evolution. Given the ability of this model inhibitor to effectively block CBS-based evolution of H~2~S from [l]{.smallcaps}-cysteine in purified enzyme assays, compound **6S** was employed as a chemical biological tool to manipulate H~2~S levels in both cell culture model systems and in an animal stroke model.

These studies show promise for the ICV delivery of hCBS inhibitors to neuronal tissue on several fronts. First, the efficacy of the *C*~2~-symmetric hydrazone former, **6S**, in competitively inhibiting H~2~S formation in the cuvette is mirrored when assaying its effect on H~2~S evolution in neuronal cell tissue culture. Second, in SH-SY5Y cerebral neuronal cell model studies employing OGD and high [l]{.smallcaps}-cysteine/[l]{.smallcaps}-homocysteine concentrations to mimic stroke-like conditions, **6S** is seen to improve cell viability. Third, this protective effect of **6S** in cell culture translates into a protective effect against cerebral infarction in a rat tMCAO model, over a 100 min occlusion window. Infarction volume is reduced by over 80% upon ICV pretreatment with **6S** (at 1.6 μmol/kg) 30 min prestroke and by nearly 70% when treatment is 1 h post-stroke. These observations point to the utility of simple chemical biological tools in projecting out toward an eventual therapeutic window for an actual treatment. Finally, in separate experiments, treatment with **6S** is also seen to dampen the inflammatory response associated with ischemia as measured by the up-regulation of the macrophage and phagocyte-specific markers, OX42 and ED1, respectively, in the tMCAO rat model and their subsequent knockdown upon **6S** treatment, in both the cerebral cortex and striatum.

The principles articulated here with respect to CBS inhibitor (i) structure (exploiting the pseudo-*C*~2~-symmetry inherent in [l]{.smallcaps},[l]{.smallcaps}-cystathionine), (ii) synthesis (demonstration of an efficient "zipped synthesis" based upon versatile cross-metathesis chemistry) and (iii) mechanism (exploiting the slow *k*~off~ rate associated with PLP-enzyme imine-hydrazone interchange--*t*(1/2)~off~ ≈ 2.5 h) will likely inform future efforts toward enzyme inhibitor design, in general, and targeted efforts toward blocking enzyme activity dependent upon pyridoxal phosphate, in particular. Compound **6S**, the first generation chemical biological tool introduced here, though not highly potent, represents a great improvement upon aminooxyacetic acid (AOAA), the relatively nonspecific PLP enzyme inhibitor that has been used in the closest previous studies. As a first pass measure of specificity, GABA AT was used as a comparison enzyme, as this is one of the best studied PLP-enzymes and one of the most important PLP enzymes in the brain (controls brain GABA levels). Whereas **6S** is a 12-fold better inhibitor of CBS (*K*~i~ ≈ 48 μM) than of GABA AT (IC(50) ≈ 572 μM), AOAA is a 33-fold better inhibitor of GABA AT (IC(50) ≈ 360 nM) than of CBS (IC(50) ≈ 12 μM)^[@ref54]^ (see [Figure S17](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.6b00019/suppl_file/oc6b00019_si_001.pdf) in the Supporting Information for details of the specificity assays). Taken together these data show that **6S** has a 400-fold specificity advantage over AOAA for CBS inhibition as opposed to GABA AT inhibition.

Of course, moving forward, it will be desirable to fine-tune the inhibitor designs identified herein so as to expand and refine the arsenal of chemical biological tools available for the study of this important hCBS enzyme. Lead compound **6S** provides a useful starting point for such studies and sets the stage for the development of second generation hCBS inhibitors wherein issues of bioavailabilty, transport, metabolism, and conformity to Lipinski's rules of five^[@ref56]−[@ref58]^ may be addressed. As was discussed at the outset, there is a major need today to better define the temporal and spatial distribution of H~2~S biogenesis and to better understand both the biological roles of H~2~S and the molecular mechanisms by which these are achieved. This study demonstrates the important role that small molecule enzyme modulators are likely to play in addressing these important questions in neuronal biology.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acscentsci.6b00019](http://pubs.acs.org/doi/abs/10.1021/acscentsci.6b00019).Details of the synthesis, complete characterization of new compounds, and procedures for all enzyme kinetics, cell culture, and animal model studies ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.6b00019/suppl_file/oc6b00019_si_001.pdf))
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